Researchers at the Virginia Commonwealth University (VCU) have identified new molecules that inhibit clotting disorders.
The researchers discovered that the identified molecules binded with Thrombin (exosite II) and inhibited the mechanism of a key enzyme that played a vital role in clotting disorders which could lead to novel therapies to treat clots in the lungs and those localized deep in the body in areas such as the legs.
Turkey Scientists Develops Drug to Stop Bleeding
Turkish scientists have created a drug stopping any bleeding in a few minutes, which means it could be used in treating haemophilia, the Sabah newspaper reported.
Advertisement
According to the study, Antithrombotic disorders occur when the effect of thrombin, a protein involved in coagulation, is inhibited, rendering blood unable to clot effectively. These disorders, which are considered common, could prove to be fatal. Additionally, clotting disorders arise due to complications from other diseases like cancer.
The study was designed of three highly complex molecules with unique anticoagulant properties that were prepared in the laboratory. These molecules, known as sulfated DHPs, were completely different from anticoagulants used in the clinic today including heparins, coumarins and hirudins.
![Protein Interaction is a Drug Target for Blood Clot Prevention]( "Protein Interaction is a Drug Target for Blood Clot Prevention")
After a blood vessel in injured, platelets cluster together to plug the site of injury in the form of a blood clot.
The researchers established that the molecules were able to inhibit the ability of critical enzymes involved with the cascade of events involved in blood clotting. Specifically, the molecules prevented the normal action of thrombin and factor Xa, which were the critical enzymes targeted by current anticoagulant therapy.
"We have identified a new mechanism that may prevent clotting. This approach may result in new drugs for the treatment of thrombotic disorders, including pulmonary embolism, deep vein thrombosis and more," said Umesh R. Desai, Ph.D., a professor in the Department of Medicinal Chemistry at the VCU School of Pharmacy
"The molecules we have designed may possess several advantages compared to currently available anticoagulation drugs. "For example, new anti-clotting therapies may result in reduced hospital stays for patients, fewer side effects, and possibly an overall cost reduction in therapy because our molecules are likely to be synthesized in an inexpensive manner," he added.
Desai and his team have now taken up the task of investigating the unit or units in the complex molecule responsible for the anti-clotting activity.
The research was supported by grants from the National Institutes of Health and the American Heart Association National Center and appeared in the Nov. 2 issue of the Journal of Biological Chemistry.
Source: ANI
LIN/C
Protein Interaction is a Drug Target for Blood Clot Prevention
After a blood vessel in injured, platelets cluster together to plug the site of injury in the form of a blood clot.
Advertisement
The researchers established that the molecules were able to inhibit the ability of critical enzymes involved with the cascade of events involved in blood clotting. Specifically, the molecules prevented the normal action of thrombin and factor Xa, which were the critical enzymes targeted by current anticoagulant therapy.
"We have identified a new mechanism that may prevent clotting. This approach may result in new drugs for the treatment of thrombotic disorders, including pulmonary embolism, deep vein thrombosis and more," said Umesh R. Desai, Ph.D., a professor in the Department of Medicinal Chemistry at the VCU School of Pharmacy
"The molecules we have designed may possess several advantages compared to currently available anticoagulation drugs. "For example, new anti-clotting therapies may result in reduced hospital stays for patients, fewer side effects, and possibly an overall cost reduction in therapy because our molecules are likely to be synthesized in an inexpensive manner," he added.
Desai and his team have now taken up the task of investigating the unit or units in the complex molecule responsible for the anti-clotting activity.
The research was supported by grants from the National Institutes of Health and the American Heart Association National Center and appeared in the Nov. 2 issue of the Journal of Biological Chemistry.
Source: ANI
LIN/C
Risk of Surgical Bleeding to Be Reduced by the Use of Recombinant Technology
Recombinant technology can ease the surgeon mind by decreasing the risk of surgical bleeding during surgery.
Advertisement
Advertisement
|
Advertisement
Latest General Health News
In India, youth must be aware of the diseases linked to cigarette smoking and tobacco consumption, causing a form of healthcare emergency.
Direct coastal access may represent a viable route to public health promotion, but the relationships of coastal living are not strongest among lower-income groups.
New research by Tinnitus UK has found that over four million gardeners are putting their hearing capacity at risk this summer without using safety protection.
Mucus plugs could be targeted to help reduce fatalities from chronic obstructive pulmonary disease.
The development of reliable curative therapies for multiple sclerosis could significantly reduce the economic burden of the disease on patients and wider society.